Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. (Q48500206)

From Wikidata

Jump to navigation Jump to search

scientific article published in July 2013

Language	Label	Description	Also known as
English	Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.	scientific article published in July 2013

Statements

scholarly article

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. (English)

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

1 reference

based on heuristic

inferred from title

drug interaction

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

object named as

Marco Siccardi

1

0 references

author name string

Catia Marzolini

2

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

Kay Seden

3

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

Lisa Almond

4

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

Anna Kirov

5

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

Saye Khoo

6

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

David Back

8

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

publication date

1 July 2013

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

52

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

583-592

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

7

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

https://scigraph.springernature.com/pub.10.1007/s40262-013-0056-7

0 references

Prevalence, correlates, and self-management of HIV-related depressive symptoms.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Current prospects for interferon-free treatment of hepatitis C in 2012.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Clinical pharmacokinetics of darunavir

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

The Simcyp population-based ADME simulator

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Maraviroc: in vitro assessment of drug-drug interaction potential

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Efavirenz: a review

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Dose-related reduction in bupropion plasma concentrations by ritonavir

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Induction of multiple drug transporters by efavirenz

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0056-7

21 January 2018

Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23479398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/23479398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23479398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23479398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4

1 reference

https://pubmed.ncbi.nlm.nih.gov/23479398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/23479398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23479398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23479398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23479398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-013-0056-7

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/23479398

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48500206&oldid=2143358121"